Autologous stem-cell collection following VTD or VRD induction therapy in multiple myeloma: a single-center experience - Archive ouverte HAL Access content directly
Journal Articles Bone Marrow Transplantation Year : 2021

Autologous stem-cell collection following VTD or VRD induction therapy in multiple myeloma: a single-center experience

(1) , (1) , (1) , (2) , (1, 3) , (1) , (1) , (1) , (1) , (1) , (1, 3) , (1) , (1) , (1) , (1) , (1, 3) , (4) , (5) , (6) , (7) , (8) , (1) , (9, 1, 3, 10) , (11, 1, 3, 10) , (9, 1, 3, 10)
1
2
3
4
5
6
7
8
9
10
11
Anne Lok
  • Function : Author
Thierry Guillaume
Pierre Peterlin
Mourad Tiab
  • Function : Author
Pascal Godmer
  • Function : Author
Adrien Trebouet
  • Function : Author

Abstract

Triplet-drug regimen bortezomib-thalidomide-dexamethasone (VTD) and bortezomib-lenalidomide-dexamethasone (VRD) are considered as standard of care induction prior autologous stem-cell transplantation (ASCT) in myeloma. In addition to improve response rate, induction therapy should preserve an adequate stem-cell collection. In the present retrospective study, we analyzed stem-cell collection in 325 newly diagnosed myeloma patients who received either VTD or VRD induction before ASCT. Stem-cell mobilization consisted of intravenous cyclophosphamide plus G-CSF. Plerixafor was administered preemptively to rescue mobilization. In comparison with VTD, VRD induction was associated with a more frequent use of plerixafor (19.3% versus 5.4%, p = 0.004) and with an increased number of apheresis to reach adequate collection (>2 apheresis required in 42.3% versus 30.2%, p = 0.05). Moreover, more patients experienced collection failure in the VRD group (6% versus 1.8%, p = 0.004). The median number of CD34-positive cells (×106/kg) was lower in the VRD group: 8.5 versus 9.3 (p = 0.05) in the VTD group. The vast majority of patients underwent ASCT (93% versus 98%, in VRD and VTD group, respectively). These data highlight the need of optimal stem-cell collection strategy, especially in the context of tandem transplantation and incorporation of anti-CD38 monoclonal antibody into induction.
Not file

Dates and versions

inserm-03495985 , version 1 (20-12-2021)

Identifiers

Cite

Vanille Laurent, Clémentine Fronteau, Chloé Antier, Pascale Dupuis, Benoit Tessoulin, et al.. Autologous stem-cell collection following VTD or VRD induction therapy in multiple myeloma: a single-center experience. Bone Marrow Transplantation, 2021, 56 (2), pp.395-399. ⟨10.1038/s41409-020-01033-8⟩. ⟨inserm-03495985⟩
25 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More